Pittsboro based biotech startup is sold to Japanese firm for $175M
Startup biotech Propella Therapeutics is being acquired by Japan-based Astella Pharma in a deal valued at $175 million. Here are the details.
Read MorePosted by WRAL TechWire | Nov 16, 2023
Startup biotech Propella Therapeutics is being acquired by Japan-based Astella Pharma in a deal valued at $175 million. Here are the details.
Read MorePosted by WRAL TechWire | Apr 8, 2022
Pittsboro-based startup Propella Therapeutics is looking to China as a market for its new osteoarthritis treatment. Here are the details.
Read MorePosted by WRAL TechWire | Feb 24, 2021
Pittsboro-based startup Propella Therapeutics is teaming up with the National Cancer Institute (NCI) to evaluate its new treatment for metastatic prostate cancer.
Read MorePosted by WRAL TechWire | Oct 8, 2020
Development-stage pharmaceutical startup Propella Therapeutics Inc. has just received a patent for its metastatic prostate cancer treatment, PRL-02. Here are the details.
Read MorePosted by WRAL TechWire | Jun 4, 2020
Propella Therapeutics, a development-stage venture focused on accelerated approvals of therapeutics with what it calls “mitigated risk,” now calls Pittsboro home.
Read More